Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
TRENDS
With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle
By Reiji Anasako As the Japanese SGLT2 inhibitor market starts to get on a growth track, competition in the crowded space is expected to heat up particularly among the top three products. First-in-class Suglat (ipragliflozin) is now closely trailed by…
To read the full story
TRENDS
- Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
- Japan SGLT2 Market Hits 70 Billion Yen as Combo Drugs Gain Ground
July 16, 2019
- Japan Drug Makers’ Workforce Down 1.3% in FY2018 amid Spate of Voluntary Redundancies
July 4, 2019
- Drug Makers Now Required to Boost Transparency in Exec Pay; Astellas Ups Bonus, Stock Option Ratio to 70%
July 3, 2019
- 12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
June 21, 2019
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…